With a market cap of $181.8 billion, Amgen Inc. (AMGN) is a world biotechnology firm that discovers, develops, manufactures, and delivers revolutionary human therapeutics for critical ailments worldwide. Headquartered in Thousand Oaks, California, Amgen serves healthcare suppliers globally and collaborates with main biopharmaceutical companions to broaden and advance its pipeline.
Firms valued at $10 billion or extra are typically thought-about “large-cap” shares, and Amgen matches this criterion completely. Its broad portfolio contains main therapies throughout irritation, oncology, heart problems, bone well being, and uncommon circumstances, with well-known merchandise resembling Enbrel, Otezla, Prolia, Repatha, and KYPROLIS.
Extra Information from Barchart
Shares of Amgen have declined 13.9% from its 52-week excessive of $391.29. Over the previous three months, its shares have fallen 13.2%, lagging behind the State Avenue Well being Care Choose Sector SPDR ETF’s (XLV) 6.7% drop throughout the identical interval.
Long term, AMGN inventory is up almost 21% over the previous 52 weeks, exceeding XLV’s 13.7% achieve. Furthermore, shares of the corporate have returned 2.9% on a YTD foundation, in comparison with XLV’s 3.4% lower over the identical timeframe.
Regardless of few fluctuations, the inventory has been buying and selling above its 50-day and 200-day transferring averages since final yr. Nevertheless, it has fallen beneath its 50-day transferring common since mid-March.
Shares of Amgen fell 4.8% following its Q1 2026 outcomes on Apr. 30, regardless of reporting adjusted EPS of $5.15, which beat expectations, and income progress of 6% to $8.6 billion. Sentiment was harm by the FDA’s proposal to withdraw approval for Tavneos, citing a lack of confirmed effectiveness and alleged false statements within the authentic software, whereas Prolia gross sales plunged 34% to $727 million, considerably beneath analyst expectations, reflecting rising competitors after patent expirations.
Though the corporate raised its full-year steering to $21.70 – $23.10 in adjusted EPS and $37.1 billion – $38.5 billion in income, issues over regulatory uncertainty surrounding Tavneos and weak point in its osteoporosis franchise outweighed the in any other case strong outcomes.